Wednesday, October 5, 2022
News
NEWS HOME
»
PRN INDIA
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML
  SocialTwist Tell-a-Friend  
   

Companion diagnostic would be used following potential regulatory approval of entospletinib to screen for NPM1 mutation present in approximately one-third of all patients with AML

Entospletinib is currently being studied in the Phase 3 AGILITY registrational study, with data anticipated in second half of 2023

SAN MATEO, Calif. and SAN DIEGO, Aug. 16, 2022 /PRNewswire/ -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of diagnostic kits and services for oncology, today announced their agreement to develop a companion diagnostic (CDx) for use with Kronos Bio's investigational therapy, entospletinib. Entospletinib is Kronos Bio's lead clinical compound, currently in the ongoing Phase 3 registrational AGILITY study for the treatment of newly diagnosed NPM1-mutated acute myeloid leukemia (AML).

Invivoscribe & Kronos Partnership

The diagnostic will screen for the NPM1 mutation, which is present in approximately one-third of all patients with AML.

Over the past year, the two companies have worked together to develop and advance the diagnostic and prepare to submit the Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) at the same time as the submission of the entospletinib New Drug Application (NDA). The FDA requires the validation and approval of companion diagnostics used to select patients for treatment with a specific therapeutic agent.

The agreement builds on Invivoscribe's experience in developing and obtaining approval for diagnostics used for identification of patients with genetically mutated AML. Invivoscribe markets an FDA-approved CDx for FLT3-mutated AML.

"This companion diagnostic NPM1  mutation assay development work with Kronos Bio represents a significant milestone for our company," said Jeffrey Miller, Ph.D., chief scientific officer and chief executive officer of Invivoscribe. "Companion diagnostics play a key role in the development and approval of targeted drug therapies and these kinds of partnerships are critical to improving care for patients with cancer."

Kronos Bio's AGILITY trial is designed to assess the efficacy and safety of entospletinib in approximately 180 adults who have been newly diagnosed with NPM1-mutated AML. In the trial, patients are being randomized to receive entospletinib or placebo, in combination with standard induction and consolidation chemotherapy. The primary endpoint of the trial is measurable residual disease (MRD) negative complete response. Event-free survival (EFS) is a key secondary endpoint, and mature EFS data are anticipated to be used to support potential full approval.

"The development of the NPM1 mutation companion diagnostic is a critical step in our efforts to rapidly advance entospletinib," said Jorge DiMartino, M.D., Ph.D., chief medical officer and executive vice president of Clinical Development at Kronos Bio. "We are fortunate to benefit from Invivoscribe's prior experience in bringing to market companion diagnostics for patients with AML."

About Kronos Bio, Inc.

Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio's lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.

Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit www.kronosbio.com or follow the company on LinkedIn.

About Invivoscribe

Invivoscribe has focused on Improving Lives with Precision Diagnostics ® for more than 28 years, advancing the field of precision medicine by developing and selling standardized reagents, tests, and bioinformatics tools to more than 700 customers in 160 countries. Invivoscribe also has a significant impact on global health working with pharmaceutical companies to accelerate approvals of new drugs and treatments by supporting international clinical trials, developing, commercializing companion diagnostics, and providing expertise in both regulatory and laboratory services. With its proven ability to provide global access to distributable reagents, kits, and controls, as well as clinical trial services through our international clinical lab subsidiaries (LabPMM), Invivoscribe has demonstrated it is an ideal partner. For additional information please visit: www.invivoscribe.com or contact Invivoscribe at:  customerservice@invivoscribe.com.

Forward-Looking Statements

Statements in this press release that are not statements of historical fact are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release, in some cases, uses terms such as "anticipated," "designed," "following," "potential," "prepare," "will," "would" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding Kronos Bio's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential successful development of a companion diagnostic for use with entospletinib; the potential submission of a PMA for such companion diagnostic; the potential validation and regulatory approval of the companion diagnostic and its use with entospletinib following approval; the potential regulatory approval of entospletinib; the anticipated use of mature EFS data to support potential full approval of entospletinib; the anticipated timing for data from the AGILITY trial; the design of the AGILITY trial; and other statements that are not historical fact. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: whether Kronos Bio and Invivoscribe will be able to successfully develop a companion diagnostic for use with entospletinib on the timeline expected, or at all, including risks related to contractual performance and Kronos Bio's reliance on Invivoscribe to complete the validation of the companion diagnostic necessary to meet regulatory requirements; whether Kronos Bio will be able to initiate, progress or complete the AGILITY trial on the timeline expected, or at all, including due to risks inherent in the clinical development of novel therapeutics; risks related to Kronos Bio's limited experience as a company in conducting clinical trials; the risk that results of preclinical studies and early clinical trials are not necessarily predictive of future results; risks related to regulatory approval of novel therapeutic products and companion diagnostics, including the risk that lack of approval of a companion diagnostic (including the companion diagnostic being developed for use with entospletinib) may jeopardize approval of the novel therapeutic product (including entospletinib); and risks associated with the sufficiency of Kronos Bio's cash resources and need for additional capital. These and other risks are described in greater detail in Kronos Bio's filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, as filed with the SEC on August 4, 2022. Any forward-looking statements that are made in this press release speak only as of the date of this press release and are based on management's assumptions and estimates as of such date. Except as required by law, Kronos Bio assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Kronos Bio Contacts:
Marni Kottle
Kronos Bio
(650) 900-3450
mkottle@kronosbio.com

Investors:
Claudia Styslinger
Argot Partners
(212) 600-1902
kronosbio@argotpartners.com

Media:
Sheryl Seapy
Real Chemistry
(949) 903-4750
sseapy@realchemistry.com

Invivoscribe Contact:
Tony Lialin
Chief Commercial Officer, Invivoscribe
tlialin@invivoscribe.com

Logo - https://mma.prnewswire.com/media/1877742/Invivoscribe_Technologies_Inc_Kronos_Bio_Partnership.jpg

More News by PR Newswire India

infodas receives NITES certification from the Cyber Security Agency of Singapore

Automation Anywhere and the Center for Humanitarian Technology Launch 'Telegram for Humanity' Bot to Aid Refugees in Ukraine

Pomerantz Law Firm Opens London Office

Sphera Completes Previously Announced Acquisition of riskmethods, a Leader in Artificial Intelligence Supply Chain Risk Management Software

Hard Rock International Celebrates 23rd Annual PINKTOBER Campaign by Partnering with World-Renowned Chef Dominique Crenn

World's Fastest Growing Staking Service Provider Born out of Lugano, Switzerland

Firmenich Annual General Meeting 2022

Unispace: Data reveals Gen Z rely on the traditional office more than any other generation

Information Office of Beijing Municipal Government' Features: "My Beijing, My Story" Depicts the Lifestyle of People Living in Beijing

Automation Anywhere Unveils the Automation Success Platform with a Surge of Innovations

Deloitte Named a Leader in Worldwide Industry Cloud Professional Services by the IDC MarketScape

HAVAS HEALTH & YOU APPOINTS PAUL PFLEIDERER AS PRESIDENT OF HAVAS LIFE NEW YORK

Solace Launches Event Portal 2.0, Addressing the Biggest Challenges Enterprises Face in Designing, Managing and Governing Event-Driven Architecture at Scale

IMG Appoints Amanda Winkle as Chief Operating Officer

Vinco Ventures Announces Ross Miller as CEO and Settlement of Litigation

RevitaLash® Cosmetics Champions Breast Cancer Awareness, Research, and Support Worldwide with 2022 Pink Program Announcement

Aspire Academy and FIFA Kick Off the 8th Global Summit with high profile FIFA guests David Beckham and Wenger

EvolveWare Facilitates Non-disruptive Application Modernization with Industry's First and Only Agile Business Rules Extraction Solution

Stamus Networks Signs Reseller Agreement with EliteVAD

China Matters' Feature: How Does Basketball Shape Dongguan's Sports Culture?

Altair Presents Open, Flexible, and Scalable Total Digital Twin Solution

IZUMA NETWORKS ACQUIRES PELION'S DEVICE MANAGEMENT BUSINESS

Globalization Partners Rebrands as G-P and Reaffirms its Promise to Make a Global Workforce Possible for Growing Companies

Secureworks State of the Threat Report 2022: 52% of ransomware incidents over the past year started with compromise of unpatched remote services

First-of-its-kind government-industry partnership announced between Deakin University, Australia and Ministry of Education and Ministry of Skill Development and Entrepreneurship, Government of India

LyondellBasell Catalyst Production Expansion Adds Life to Infrastructure Projects

BE EVERYTHING - A new chapter opens in the story of United Colors of Benetton: new creative director, Andrea Incontri presents his first fashion show

PwC announces record global revenues of US$50 billion

Challenge the Highest Level of <MIR4>! A New Content, Hell Raid, Unveiled

Leading Gaming technology provider Quixant announces the launch of new cabinet offering

StoreHippo® launches Mystore Buyer and Seller Apps for ONDC

Cambrex Announces Stability Storage Expansions in Ireland and Belgium

TimesPro collaborates with IMT Hyderabad to launch programmes in Business & Retail Management

Industrial Transformation ASIA-PACIFIC 2022 returns to catalyse sustainable growth for advanced manufacturing in the region

The PI Group and Averna Announce their Partnership

Academic partnerships in focus, Global Education Summit commences at Chandigarh University

UST and Mendix Collaborate to Accelerate Low Code Development in Spain

Nestlé launches NESCAFÉ Plan 2030 to help drive regenerative agriculture, reduce greenhouse gas emissions and improve farmers' livelihoods

Ingenico Launches as Independent Company Following Acquisition by Apollo Private Equity Funds

Stockify announces single-window online service to buy unlisted equities

Manipal Hospital Whitefield's Exclusive Take on Minimally Invasive Advanced Surgical Procedures (MIAS)

THE LEELA PALACES, HOTELS AND RESORTS PARTNERS WITH RAJASTHAN POLO CLUB FOR ITS INAUGURAL SPONSORSHIP OF THE ROYAL SPORT IN INDIA

CLO Virtual Fashion Announces the Acquisition of GoVise Technologies

Education Cannot Wait Announces US$11.8 Million Catalytic Grant in Haiti

DXC Technology Calls for Latest Innovations from Insurance Startups and Scaleups across Asia Pacific through the DXC Invitational

Global AdTech Company TripleLift Names Dave Clark as New Chief Executive Officer

Navneeth Sulakhe joins Innoviti as Senior VP Human Resource Management

KEI Wires & Cables Hosts Real Kabbadi League Season 2

Automation Anywhere Secures $200 Million in Financing from Silicon Valley Bank and Hercules Capital

2022 World Trade Centers Association Member Forum Returns to New York City for First Time in Two Years

TATA POWER REINFORCES COMMITMENT TOWARDS GREEN ECOSYSTEM CONSERVATION ACROSS ITS RENEWABLE SITES

Azure Power wins the prestigious Golden Peacock Award for Sustainability

FANDOM ACQUIRES LEADING ENTERTAINMENT & GAMING BRANDS INCLUDING GAMESPOT, TV GUIDE AND METACRITIC

National Engineering Industries Ltd (NBC Bearings) honored with 'Iconic Brands of India 2022'

Celebrating Glorious 35 Years of BIMTECH

HABANOS, S.A. PRESENTED THE MONTECRISTO WIDE EDMUNDO IN WORLD PREMIERE IN SPAIN

Sanjay Ghodawat Foundation awarded The Mahatma Award 2022

STL announces Gram Galaxy - India's first integrated solution to connect villages with fibre

DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY

Healthium Medtech amongst the first in Asia and first Indian Medtech Company to receive CE certification under the EU MDR (European Union Medical Device Regulation) norms for Class III implants

Jagadguru Kripalu Parishat holds Grand Rath Yatra on 3rd October 2022 near Kunda, Pratapgarh in honor of the 100th Birth Anniversary of Jagadguru Shri Kripalu Ji Maharaj

Addteq APAC Announces Rebranding, Changes Name to Enreap

Karwa Chauth 2022: FlowerAura Is All Geared Up To Enhance The Celebrations

DMCC AWARDED GLOBAL FREE ZONE OF THE YEAR FOR EIGHTH CONSECUTIVE YEAR

New Book Property Tax in Asia Provides the First Comprehensive Analysis of the Property Tax Across the World's Largest Continent

UN WOMEN'S HeForShe EXPANDS MOVEMENT THROUGH KEY PUBLIC AND PRIVATE PARTNERSHIPS IN EAST ASIA

STL unveils 5G cosmos to help Indian telcos fiberise their networks for 5G

STL launches Multiverse - India's first Multicore fibre and cable; aims to revolutionize the optical landscape

Tejas Networks successfully demonstrates end-to-end network based on its indigenous 4G/5G wireless, optical and satellite products

IIIT Hyderabad and Silicon Labs Launch Campus-wide Wi-SUN Network for Smart City Applications

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Hyderabad Police arrests one in dating f...
UKSSSC paper leak case: Illegally constr...
Punjab DGP forms 4-member SIT to probe g...
Gehlot vs Pilot: Former deputy CM opens ...
300 youth take part in Yogasana competit...
TN whistleblower's murder: Activists see...
More...    
 
 Top Stories
Kajol, Revathi seek blessings from ... 
Russia ready to negotiate with curr... 
Punjab DG sets up SIT to unravel co... 
PGTI Players Championship: Jamal Ho... 
Shivaani Singh talks about playing ... 
Mahishasura idol resembling Mahatma... 
Automation Anywhere introduces new ... 
Explainer: Will your current smartp...